JP2016199549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016199549A5 JP2016199549A5 JP2016095779A JP2016095779A JP2016199549A5 JP 2016199549 A5 JP2016199549 A5 JP 2016199549A5 JP 2016095779 A JP2016095779 A JP 2016095779A JP 2016095779 A JP2016095779 A JP 2016095779A JP 2016199549 A5 JP2016199549 A5 JP 2016199549A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 claims description 133
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 claims description 133
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 90
- 239000012634 fragment Substances 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 78
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 44
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 44
- 208000014951 hematologic disease Diseases 0.000 claims description 33
- 230000003211 malignant effect Effects 0.000 claims description 33
- 208000019838 Blood disease Diseases 0.000 claims description 32
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000003902 lesion Effects 0.000 claims description 30
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims description 29
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims description 29
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 27
- 230000002159 abnormal effect Effects 0.000 claims description 23
- 210000001185 bone marrow Anatomy 0.000 claims description 21
- 101710085938 Matrix protein Proteins 0.000 claims description 20
- 101710127721 Membrane protein Proteins 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 201000009295 smoldering myeloma Diseases 0.000 claims description 18
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims description 17
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 210000004180 plasmocyte Anatomy 0.000 claims description 16
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims description 14
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims description 14
- 210000000822 natural killer cell Anatomy 0.000 claims description 14
- 208000032839 leukemia Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 8
- 230000002584 immunomodulator Effects 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 7
- 230000008707 rearrangement Effects 0.000 claims description 7
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010067477 Cytogenetic abnormality Diseases 0.000 claims description 5
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108010069149 HLA-C*04 antigen Proteins 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 claims description 3
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 claims description 3
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims description 3
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 3
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000013059 antihormonal agent Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000010837 poor prognosis Methods 0.000 claims description 3
- 230000017854 proteolysis Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 8
- 230000005856 abnormality Effects 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 238000011443 conventional therapy Methods 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101150010487 are gene Proteins 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 131
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 74
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 74
- 239000000203 mixture Substances 0.000 description 21
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41597310P | 2010-11-22 | 2010-11-22 | |
| US61/415,973 | 2010-11-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Division JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016199549A JP2016199549A (ja) | 2016-12-01 |
| JP2016199549A5 true JP2016199549A5 (enExample) | 2017-03-09 |
Family
ID=46146390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Expired - Fee Related JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
| JP2016095779A Pending JP2016199549A (ja) | 2010-11-22 | 2016-05-12 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541022A Expired - Fee Related JP6224457B2 (ja) | 2010-11-22 | 2011-11-22 | Ｎｋ細胞調節治療及び悪性血液疾患の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9844593B2 (enExample) |
| EP (1) | EP2643350A4 (enExample) |
| JP (2) | JP6224457B2 (enExample) |
| CN (2) | CN106963947A (enExample) |
| AR (1) | AR083957A1 (enExample) |
| BR (1) | BR112013012138B1 (enExample) |
| CA (1) | CA2818684C (enExample) |
| EA (1) | EA035033B1 (enExample) |
| MX (1) | MX355483B (enExample) |
| TW (1) | TWI664191B (enExample) |
| WO (1) | WO2012071411A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| EP3072522B1 (en) * | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| EP2714741B1 (en) * | 2011-05-25 | 2019-10-30 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
| US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| US20150290316A1 (en) | 2012-10-02 | 2015-10-15 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| CN107880126B (zh) | 2012-12-21 | 2021-03-30 | 西雅图基因公司 | 抗ntb-a抗体及相关组合物和方法 |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| JP6856188B2 (ja) * | 2013-05-03 | 2021-04-07 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｃｓ１特異的キメラ抗原受容体を遺伝子操作した免疫エフェクター細胞 |
| ES2707057T3 (es) | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| CN107530424A (zh) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| RU2571551C1 (ru) * | 2015-04-16 | 2015-12-20 | Закрытое акционерное общество "ПЕПТЕК" | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором |
| SG10201912035YA (en) | 2015-04-17 | 2020-02-27 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| ES2905525T3 (es) | 2015-05-06 | 2022-04-11 | Snipr Tech Ltd | Alteración de poblaciones microbianas y modificación de la microbiota |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| KR102554507B1 (ko) | 2015-07-24 | 2023-07-11 | 이나뜨 파르마 에스.에이. | 조직 침윤성 nk 세포를 검출하는 방법 |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| CN109890387B (zh) | 2016-05-20 | 2022-06-14 | 拜尔哈文制药股份有限公司 | 谷氨酸调节剂与免疫疗法用以治疗癌症的用途 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| AU2017335732B2 (en) | 2016-09-27 | 2024-11-21 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
| KR102661905B1 (ko) | 2016-10-12 | 2024-04-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Tusc2 면역요법을 위한 방법 및 조성물 |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| CN110520157A (zh) * | 2017-02-09 | 2019-11-29 | 纪念斯隆凯特琳癌症中心 | 抗-kir3dl1抗体 |
| AU2018246235B2 (en) | 2017-03-27 | 2023-12-21 | National University Of Singapore | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| SG10202110594UA (en) | 2017-03-31 | 2021-11-29 | Bristol Myers Squibb Co | Methods of treating tumor |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US12454561B2 (en) | 2018-03-19 | 2025-10-28 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| BR112020019418A2 (pt) | 2018-03-25 | 2021-02-17 | Snipr Biome Aps. | tratamento e prevenção de infecções microbianas |
| CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| WO2019193476A1 (en) | 2018-04-02 | 2019-10-10 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019195769A1 (en) * | 2018-04-06 | 2019-10-10 | The Brigham And Women's Hospital, Inc. | Methods of diagnosing and treating aggressive cutaneous t-cell lymphomas |
| CN108728527B (zh) * | 2018-06-06 | 2020-06-09 | 青岛泱深生物医药有限公司 | Hcst基因作为诊治子痫前期的靶标 |
| EP3806848A2 (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL297931B2 (en) | 2018-09-25 | 2025-03-01 | Harpoon Therapeutics Inc | DLL3 binding proteins and methods of use |
| KR20210109564A (ko) | 2018-12-21 | 2021-09-06 | 옹쎄오 | 신규의 컨쥬게이티드 핵산 분자 및 이의 용도 |
| KR102210455B1 (ko) * | 2019-02-28 | 2021-02-02 | 사회복지법인 삼성생명공익재단 | 자연살해세포 활성 검출용 미세입자 및 이를 이용한 검출 방법 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| CN114222761B (zh) * | 2020-07-14 | 2024-02-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| EP4247940A4 (en) * | 2020-11-18 | 2025-01-01 | The Regents of the University of California | REMOVAL OF MONOCLONAL ANTIBODIES AGAINST NATURAL KILLER CELLS |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| PL4267105T3 (pl) | 2020-12-28 | 2025-06-30 | Bristol-Myers Squibb Company | Kompozycje przeciwciał i metody ich stosowania |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| JP2024527925A (ja) * | 2021-07-28 | 2024-07-26 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｉｌｔ３抗体による急性骨髄性白血病の治療方法 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
| CN118871451A (zh) | 2022-03-18 | 2024-10-29 | 百时美施贵宝公司 | 分离多肽的方法 |
| CN119562830A (zh) | 2022-06-02 | 2025-03-04 | 百时美施贵宝公司 | 抗体组合物及其使用方法 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP1556033A4 (en) | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| WO2005003168A2 (en) | 2003-07-02 | 2005-01-13 | Novo Nordisk A/S | Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies |
| CN1852924A (zh) * | 2003-07-02 | 2006-10-25 | 依奈特制药公司 | Pan－kir2dl nk－受体的抗体及其在诊断及治疗中的应用 |
| US7803376B2 (en) * | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| JP5295568B2 (ja) | 2005-01-06 | 2013-09-18 | ノヴォ ノルディスク アー／エス | Ｋｉｒ結合剤およびその使用方法 |
| AU2008204433B2 (en) | 2007-01-11 | 2014-03-13 | Novo Nordisk A/S | Anti-KIR antibodies, formulations, and uses thereof |
| US20100099084A1 (en) | 2008-10-17 | 2010-04-22 | Maher Albitar | Detection of npm1 nucleic acid in acellular body fluids |
-
2011
- 2011-11-22 CA CA2818684A patent/CA2818684C/en active Active
- 2011-11-22 CN CN201710194545.4A patent/CN106963947A/zh active Pending
- 2011-11-22 CN CN2011800622682A patent/CN103298831A/zh active Pending
- 2011-11-22 MX MX2013005673A patent/MX355483B/es active IP Right Grant
- 2011-11-22 US US13/988,954 patent/US9844593B2/en active Active
- 2011-11-22 TW TW100142827A patent/TWI664191B/zh active
- 2011-11-22 EA EA201390756A patent/EA035033B1/ru not_active IP Right Cessation
- 2011-11-22 WO PCT/US2011/061840 patent/WO2012071411A2/en not_active Ceased
- 2011-11-22 JP JP2013541022A patent/JP6224457B2/ja not_active Expired - Fee Related
- 2011-11-22 AR ARP110104349A patent/AR083957A1/es unknown
- 2011-11-22 BR BR112013012138-6A patent/BR112013012138B1/pt not_active IP Right Cessation
- 2011-11-22 EP EP11843281.4A patent/EP2643350A4/en not_active Ceased
-
2016
- 2016-05-12 JP JP2016095779A patent/JP2016199549A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016199549A5 (enExample) | ||
| JP2014501729A5 (enExample) | ||
| US20220332816A1 (en) | Anti-tigit antibodies | |
| US8758749B2 (en) | Biological materials and uses thereof | |
| AU2018266784B2 (en) | LRRC33 inhibitors and use thereof | |
| JP2018502892A (ja) | ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ | |
| US10611839B2 (en) | Anti CD84 antibodies, compositions comprising same and uses thereof | |
| US20230348611A1 (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| BR112013032217B1 (pt) | uso de um anticorpo anti-nkg2a | |
| KR20190038919A (ko) | 항-nkg2d 항체로 크론병을 치료하는 방법 | |
| TW202133877A (zh) | 全身性紅斑狼瘡中之ｉ型干擾素抑制 | |
| US11136383B2 (en) | Methods and compositions for modulaton of transforming growth factor beta-regulated functions | |
| EP3986462A2 (en) | Anti-tim-3 antibodies | |
| US12116415B2 (en) | Anti-BCMA antibodies | |
| US12415851B2 (en) | Monoclonal antibodies to ELTD1 and uses thereof | |
| CN105492023A (zh) | Tspan 33是用于治疗b细胞霍奇金淋巴瘤的抗体靶向疗法的候选物 | |
| WO2025085512A1 (en) | Combination therapies with ulbp2 targeting antibodies for treating cancers | |
| Moszczuk et al. | The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies | |
| JP2023523450A (ja) | 非小細胞肺がん免疫療法のための方法及び組成物 | |
| US20250320294A1 (en) | Bispecific antibody for t-cell modulation | |
| CA3048198A1 (en) | Methods of treating multiple myeloma | |
| CN117355330A (zh) | 抗cd19组合疗法 | |
| HK40103766A (en) | Lrrc33 inhibitors and use thereof |